Polyphor and EnBiotix sign merger agreement and agreement on sale of Murapavadin
2. September 2021 – Polyphor (SIX: POLN) and EnBiotix Inc., a privately held late clinical-stage rare disease company currently focused on products for rare, chronic respiratory diseases, have signed a merger agreement pursuant to which Polyphor acquires all of the outstanding capital stock of EnBiotix in exchange for shares of Polyphor common stock. EnBiotix also acquires Inhaled Murepavadin at an agreed valuation of USD 10m in exchange for 2'599'655 of common shares of EnBiotix. The completion of merger will create a late stage clinical development company with two clinical programs in cystic fibrosis.
Walder Wyss advises Enbiotix Inc. on this transaction. The Walder Wyss team was led by Alexander Gutmans (Partner, Corporate/M&A and Venture Capital) and included Alex Nikitine (Partner, Corporate/M&A), Michelle Bruni (Senior Associate, Corporate/M&A and Tax), Daniel Dedeyan (Counsel, Banking and Finance) and Karina Tschon (Associate, Corporate/M&A and Venture Capital).